TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07753850: A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SL-325 in Participants With Moderately to Severely Active Crohn's Disease

Sponsor: Shattuck Labs, Inc. · Phase: PHASE2 · Area: IMMUNOLOGY · Target Enrollment: 232 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$7,038,000

Rescue Site Savings

+$4,657,500

Unlock Full NCT07753850 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07753850 Rescue Dossier →